VolitionRx Secures $6.25M in Convertible Debt Financing

In May, Stradling represented VolitionRx, a company which, through its subsidiaries, is developing and commercializing simple, easy-to-use, cost-effective blood tests to diagnose and monitor a range of diseases, including some cancers, diseases associated with NETosis and sepsis, with a debt financingproviding $6.25 Million in gross proceeds pursuant to a Secured Convertible Promissory Note, plus a warrant to purchase Common Stock which, if exercised in full, will result in potential approximate gross proceeds of up to an additional $8.75 million. 

The $7.5M ATM was also publicly disclosed in our prospectus supplement filing with the SEC.